Europe's Last Chance To Revive Its Pharmaceutical Innovation Power

Europe's biopharmaceutical innovation capacity has been in gradual decline for decades, and the article warns that China's rapid rise and policy shifts under President Trump risk accelerating that erosion. The key implication is a weakening of Europe's long-term competitive position in biotech and potential downward pressure on R&D productivity and returns for European pharma. Portfolio actions: reassess exposure to legacy European pharma without strong global R&D footprints, favor companies with resilient pipelines or diversified manufacturing, and monitor trade/regulatory developments closely.

Analysis

Europe's biopharmaceutical innovation capacity has been in gradual decline for decades, and the article warns that China's rapid rise and policy shifts under President Trump risk accelerating that erosion. The key implication is a weakening of Europe's long-term competitive position in biotech and potential downward pressure on R&D productivity and returns for European pharma. Portfolio actions: reassess exposure to legacy European pharma without strong global R&D footprints, favor companies with resilient pipelines or diversified manufacturing, and monitor trade/regulatory developments closely.